Indraprastha Medical Corporation Limited (NSE:INDRAMEDCO)
379.80
-3.15 (-0.82%)
May 9, 2025, 3:29 PM IST
NSE:INDRAMEDCO Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
Cash & Equivalents | - | 616 | 522.6 | 417.4 | 249.2 | 203.32 | Upgrade
|
Short-Term Investments | - | 1,603 | 739.5 | 242.7 | - | - | Upgrade
|
Cash & Short-Term Investments | 3,094 | 2,219 | 1,262 | 660.1 | 249.2 | 203.32 | Upgrade
|
Cash Growth | 49.21% | 75.78% | 91.20% | 164.89% | 22.56% | 20.89% | Upgrade
|
Accounts Receivable | - | 642.6 | 746.2 | 481.3 | 720.8 | 840.59 | Upgrade
|
Other Receivables | - | 6.1 | 4 | 214.5 | 223.5 | 139.82 | Upgrade
|
Receivables | - | 648.7 | 750.2 | 695.8 | 944.3 | 982.92 | Upgrade
|
Inventory | - | 75.3 | 84.5 | 99.9 | 87.4 | 120.66 | Upgrade
|
Prepaid Expenses | - | 101.8 | 100.8 | 89.4 | 104.3 | 61.32 | Upgrade
|
Other Current Assets | - | 35.5 | 33.2 | 29.1 | 29.1 | 46.5 | Upgrade
|
Total Current Assets | - | 3,080 | 2,231 | 1,574 | 1,414 | 1,415 | Upgrade
|
Property, Plant & Equipment | - | 3,464 | 2,766 | 2,752 | 2,833 | 3,013 | Upgrade
|
Long-Term Investments | - | 605.2 | 455.1 | 230.1 | - | - | Upgrade
|
Other Intangible Assets | - | 10.5 | 9.6 | 17.1 | 33.8 | 14.02 | Upgrade
|
Other Long-Term Assets | - | 73.3 | 89.7 | 44.1 | 38.6 | 48.44 | Upgrade
|
Total Assets | - | 7,232 | 5,551 | 4,617 | 4,320 | 4,490 | Upgrade
|
Accounts Payable | - | 773.5 | 588.7 | 390.9 | 397.9 | 433.09 | Upgrade
|
Accrued Expenses | - | 694.3 | 534.9 | 414.9 | 647.1 | 758.81 | Upgrade
|
Short-Term Debt | - | - | - | - | - | 39.75 | Upgrade
|
Current Portion of Leases | - | 16.8 | 24.8 | 28.3 | 25.1 | 20.93 | Upgrade
|
Current Income Taxes Payable | - | 5.8 | 44.2 | - | - | - | Upgrade
|
Current Unearned Revenue | - | 88 | 69.4 | 68.7 | 45.5 | 57.26 | Upgrade
|
Other Current Liabilities | - | 75.8 | 34.3 | 32.2 | 43.4 | 86.21 | Upgrade
|
Total Current Liabilities | - | 1,654 | 1,296 | 935 | 1,159 | 1,396 | Upgrade
|
Long-Term Leases | - | 322.7 | - | 24.8 | 53 | 78.18 | Upgrade
|
Long-Term Deferred Tax Liabilities | - | 197.2 | 199.8 | 231.9 | 222.6 | 202.57 | Upgrade
|
Other Long-Term Liabilities | - | 280.7 | 260.8 | 17.9 | 19.8 | 22.46 | Upgrade
|
Total Liabilities | - | 2,455 | 1,757 | 1,363 | 1,592 | 1,812 | Upgrade
|
Common Stock | - | 916.7 | 916.7 | 916.7 | 916.7 | 916.73 | Upgrade
|
Retained Earnings | - | 3,983 | 3,018 | 2,386 | 1,800 | 1,776 | Upgrade
|
Comprehensive Income & Other | - | -121.8 | -140.3 | -48.1 | 11.2 | -15.1 | Upgrade
|
Shareholders' Equity | 5,244 | 4,778 | 3,795 | 3,254 | 2,728 | 2,678 | Upgrade
|
Total Liabilities & Equity | - | 7,232 | 5,551 | 4,617 | 4,320 | 4,490 | Upgrade
|
Total Debt | 327.4 | 339.5 | 24.8 | 53.1 | 78.1 | 138.86 | Upgrade
|
Net Cash (Debt) | 2,766 | 1,879 | 1,237 | 607 | 171.1 | 64.46 | Upgrade
|
Net Cash Growth | 36.50% | 51.86% | 103.84% | 254.76% | 165.44% | - | Upgrade
|
Net Cash Per Share | 30.18 | 20.50 | 13.50 | 6.62 | 1.87 | 0.70 | Upgrade
|
Filing Date Shares Outstanding | 91.65 | 91.67 | 91.67 | 91.67 | 91.67 | 91.67 | Upgrade
|
Total Common Shares Outstanding | 91.65 | 91.67 | 91.67 | 91.67 | 91.67 | 91.67 | Upgrade
|
Working Capital | - | 1,426 | 934.5 | 639.3 | 255.3 | 18.67 | Upgrade
|
Book Value Per Share | 57.27 | 52.12 | 41.39 | 35.50 | 29.75 | 29.21 | Upgrade
|
Tangible Book Value | 5,236 | 4,767 | 3,785 | 3,237 | 2,694 | 2,664 | Upgrade
|
Tangible Book Value Per Share | 57.18 | 52.00 | 41.29 | 35.31 | 29.38 | 29.06 | Upgrade
|
Buildings | - | 1,988 | 1,929 | 1,898 | 1,873 | 1,873 | Upgrade
|
Machinery | - | 3,247 | 2,855 | 2,603 | 2,479 | 2,429 | Upgrade
|
Construction In Progress | - | 4.7 | 25.3 | - | 33.3 | - | Upgrade
|
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.